Merck's pause on an HIV program snowballs as a Gilead-partnered trial is shoved into limbo
Merck’s announcement last week that an experimental HIV combo therapy resulted in a drop in immune cell counts, and its subsequent decision to halt …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
